Kodiak Sciences, Inc. (KOD)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Kodiak Sciences, Inc. (KOD)
Go deeper and ask any question about KOD
Company Performance
Current Price
as of Sep 13, 2024$2.71
P/E Ratio
N/A
Market Cap
$142.59M
Description
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Metrics
Overview
- HQPalo Alto, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerKOD
- Price$2.71+13.87%
Trading Information
- Market Cap$142.59M
- Float92.57%
- Average Daily Volume (1m)153,780
- Average Daily Volume (3m)246,172
- EPS-$3.77
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$45.12M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$41.30M
- EV$80.03M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account